![<scp>TRE</scp>
atment of
<scp>AT</scp>
opic eczema (
<scp>TREAT</scp>
) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema]()
<scp>TRE</scp>
atment of
<scp>AT</scp>
opic eczema (
<scp>TREAT</scp>
) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczemaBosma, A.L.; Spuls, P.I.; Garcia‐Doval, I.; Naldi, L.; Prieto‐Merino, D.; Tesch, F.; Apfelbacher, C.J.; Arents, B.W.M.; Barbarot, S.; Baselga, E.; Deleuran, M.; Eichenfield, L.F.; Gerbens, L.A.A.; Irvine, A.D.; Manca, A.; Mendes‐Bastos, P.; Middelkamp‐Hup, M.A.; Roberts, A.; Seneschal, J.; Svensson, Å.; Thyssen, J.P.; Torres, T.; Vermeulen, F.M.; Vestergaard, C.; von Kobyletzki, L.B.; Wall, D.; Weidinger, S.; Schmitt, J.; Flohr, C. · British Journal of Dermatology · 2019